![Adverse pregnancy outcomes associated with thrombophilias [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2015/07/Classics-2-Minute-Medicine-e1436017941513-350x250.png)
The EMGT: Reducing intraocular pressure slows progression of glaucoma [Classics Series]
1. Treatment using laser trabeculoplasty and topical betaxolol hydrochloride to reduce intraocular pressure (IOP) is associated with delayed progression of...
The MDRD trial: Protein intake and blood pressure control in renal insufficiency [Classics Series]
1. Reducing protein intake and lower blood pressure targets did not significantly delay the rate of decline in GFR in...
The NETT: Lung-volume-reduction surgery in emphysema
Image: PD 1. Lung-volume-reduction surgery significantly improves exercise capacity, but not overall survival, in patients with emphysema when compared with...
The RENAAL Trial: Losartan in diabetic nephropathy [Classics Series]
Image: PD 1. In patients with type II diabetes and nephropathy, losartan at a dose of 50-100 mg daily significantly...
The DASH trial: Diet change significantly reduces blood pressure [Classics Series]
Image: PD 1. A “combination” diet rich in fruits and vegetables and low in saturated and total fat reduces blood...
The PLCO trial 1: PSA and digital rectal examination in prostate cancer screening [Classics Series]
Image: PD 1. Subjects undergoing annual prostate-specific antigen (PSA) testing for 6 years and annual digital rectal examination (DRE) for...
The PLCO trial 2: Flexible sigmoidoscopy in colon cancer screening [Classics Series]
Image: PD 1. Screening with flexible sigmoidoscopy is associated with a significant decrease in colon cancer incidence in the distal...
The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]
Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and...
The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]
Image: PD 1. Valsartan, an angiotensin-receptor blocker, significantly reduces morbidity, but not mortality, in heart failure patients when added to...